<DOC>
	<DOCNO>NCT01413178</DOCNO>
	<brief_summary>The goal clinical research study compare Busulfex ( busulfan ) without Alkeran ( melphalan ) learn study therapy may better help control MM patient receive autologous stem cell transplant . The safety combination therapy also study . Melphalan busulfan design damage DNA ( genetic material ) cell , may cause cancer cell die .</brief_summary>
	<brief_title>A Randomized Trial Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 Preparative Regimen Autologous Hematopoietic Stem Cell Transplantation Multiple Myeloma</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group . - Group 1 receive melphalan busulfan . - Group 2 receive melphalan . Both group stem cell transplant . Study Drug Administration : If Group 1 , first receive additional low-level `` test '' dose busulfan give vein check blood level change time . This information use decide next dose need reach target blood level busulfan . Blood ( 1 teaspoon time ) drawn 11 time next 11 hour test dose first high-dose busulfan treatment . A heparin lock line place vein low number needle stick need draws . This test dose busulfan give outpatient admit hospital , admit Day -10 ( 10 day transplant ) receive test dose Day -9 . If possible blood level test perform technical scheduling reason , receive standard , fix ( unchanging ) dose busulfan . Eight ( 8 ) 10 day transplant , admit hospital give hydration fluid vein . On Days -7 , -6 , -5 , -4 , receive busulfan vein 3 hour . You receive melphalan Days -2 -1 vein 30 minute . You receive stem cell transplant CVC Day 0 . If Group 2 , may admit hospital 3 day transplant . You receive hydration fluid vein . Two ( 2 ) day transplant , receive melphalan vein 30 minute . You receive melphalan day transplant . Stem Cell Transplant : The day receive stem cell transplant call Day 0 . The stem cell give vein CVC . The cell travel bone marrow design start make healthy , new blood cell several week . You sign separate consent collection stem cell . Beginning 5 day transplant , receive filgrastim ( G-CSF ) needle skin 1 time day blood cell level return normal . Filgrastim design help growth white blood cell . You hospital transplant 2-4 week . Questionnaire : You ask complete quality-of-life questionnaire start study drug week Weeks 1 , 2 , 4 stem cell transplant . The questionnaire take 15 minute complete . Follow-Up Visits : About 3 month transplant , bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration biopsy , area hip numb anesthetic , small amount bone marrow bone withdrawn large needle . Every 3 month first year transplant , blood ( 1-2 tablespoon ) draw check immune response status disease . About 1 year transplant , bone scan doctor think need . Length Study : One ( 1 ) year transplant , participation study . If intolerable side effect chemotherapy occur sign disease transplant , take study . If intolerable side effect receive chemotherapy , still transplant . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . This investigational study . Busulfan melphalan commercially available FDA approve treatment myeloma . The use melphalan alone autologous stem cell transplant consider standard care . Using busulfan melphalan investigational . Up 205 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients multiple myeloma complete remission ( CR ) , partial remission ( PR ) , good partial remission ( VGPR ) , symptomatic stable disease ( evidence progression ) include patient light chain MM detect serum free light chain assay . 2 . Patients nonsecretory multiple myeloma [ absence monoclonal protein ( M protein ) serum measure electrophoresis ( SPEP ) immunofixation ( SIFE ) absence Bence Jones protein urine ( UPEP ) define use conventional electrophoresis immunofixation ( UIFE ) techniques ] measurable disease image study like MRI , CT scan PET scan . 3. Who receive least two cycle initial systemic therapy within 2 12 month first dose . Mobilization therapy consider initial therapy . 4 . 70 year age young . 5 . Karnofsky performance score 70 % high . 6 . Cardiac function : leave ventricular ejection fraction rest &gt; 40 % within 3 month registration . 7 . Hepatic function : bilirubin &lt; 2x upper limit normal ALT AST &lt; 2.5x upper limit normal . 8 . Renal function : creatinine clearance &gt; /= 40 mL/min , estimate calculate . 9 . Pulmonary function : DLCO , FEV1 , FVC &gt; /= 50 % predict value ( correct hemoglobin ) within 3 month registration 10 . Signed informed consent form . 1 . Patients uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) . 2 . Patients seropositive human immunodeficiency virus ( HIV ) . 3 . Patients history myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 4 . Patients participate investigational new drug protocol within 14 day enrollment . 5 . Female patient pregnant ( positive bHCG ) breastfeeding . 6 . Prior stem cell transplantation allogeneic autologous . 7 . Prior organ transplant require immunosuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Light chain Multiple Myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Autologous Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>NeupogenTM</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
	<keyword>Quality Life</keyword>
	<keyword>QOL</keyword>
</DOC>